Myeloid sarcoma
Therapeutic area
Oncology
Rare disease
Yes
- Definition
- A tumor mass composed of myeloblasts or immature myeloid cells. It occurs in extramedullary sites or the bone. (WHO, 2001)
- Genetic basis
- No
- Non-human condition
- No
- Rare disease
- Yes
- Listing at source
- Listed
- Condition name
- Myeloid sarcoma
- Therapeutic area
- Oncology
- myeloid sarcoma
- chloroma
- extramedullary myeloid tumor
- extramedullary myeloid tumour
- myeloid sarcoma
- sarcoma, myeloid, malignant
- MS
- Severity
- Severe
- Hematology
- Immunology
- Oncology
- Rheumatology
- MONDO ID
- MONDO:0006861
- Parent condition
- MONDO:0005089
Related records
Broader conditions (34)
- Acute disease
- Acute leukemia
- Acute myeloid leukemia
- Acute myeloid leukemia by FAB classification
- Bone cancer
- Bone disorder
- Bone marrow cancer
- Bone marrow disorder
- Bone marrow neoplasm
- Bone neoplasm
- Cancer
- Cancer or benign tumor
- Connective tissue disorder
- Connective tissue neoplasm
- Disease
- Disease by body system or component
- Disease by etiologic mechanism
- Hematologic disorder
- Hematopoietic and lymphoid cell neoplasm
- Hematopoietic and lymphoid system neoplasm
Narrower conditions (1)
- Granulocytic sarcoma
Trials (93)
- "Selfie" Videos: A Novel, Patient-centered, Comprehensive Approach to Measuring Function in MS
- A Closed Loop, Doctor to Patient, Mobile Application for Depression in People With Multiple Sclerosis
- A Multicenter Clinical Trial Evaluating the Efficacy and Safety of Taurine as an Adjunctive Therapy in Multiple Sclerosis
- A Non-Interventional Pilot Study to Explore the Role of Gut Flora in Disease
- A Pilot Study of Warm and Cold Compress to Reduce Injection Site Erythema Due to Peginterferon-beta-1a in MS
- A Pilot Study to Explore the Role of Gut Flora in Multiple Sclerosis
- A Study of Orelabrutinib in Patients With Primary Progressive Multiple Sclerosis
- A Study of RD06-04 in Patients With Active Autoimmune Diseases
- A Study of Remibrutinib Using MR Imaging in Relapsing or Progressive MS
- A Study to Investigate the Safety and Tolerability of Ziftomenib in Combination With Venetoclax/Azacitidine, Venetoclax, 7+3, or 7+3+Quizartinib in Patients With AML
- A Therapeutic Experience Program (TEP) Study for Improvement of Gait in People With Multiple Sclerosis (MS)
- Acute Intermittent Hypoxia Combined With Gait Training in Multiple Sclerosis
- Assessment of Transcranial Alternating Current Stimulation's Clinical Efficacy in Treating Cognitive Impairment of Idiopathic Inflammatory Demyelinating Diseases
- At Home Use of Stimulation Suits for Managing MS Symptoms
- Behavioral and Electrophysiological Evidence of the Modulation of Fatigue in RR-MS
- Blood Flow Restriction Training in Multiple Sclerosis
- Bortezomib and Sorafenib Tosylate in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia
- Brain Functional Connectivity Changes Following Cognitive Rehabilitation in Multiple Sclerosis: an fMRI Study
- Brain Imaging and Immune Changes During Remibrutinib Treatment in Multiple Sclerosis.
- CD19/BCMA-Targeted UCAR-T for Patients With Neurological Autoimmune Diseases
Drugs in development (6)
- Asparaginase Phase 3
- Cytarabine Phase 3
- Daunorubicin hydrochloride Phase 3
- Etoposide Phase 3
- Mitoxantrone hydrochloride Phase 3
- Sorafenib tosylate Phase 3